Frank Mottola - 29 Jul 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: SVP, Chief Tech. Ops. Officer
Issuer ticker: SUPN
Reported as of: 29 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Jul 2026, 17:05:11 UTC
Prior SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

Frank Mottola filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 31 Jul 2026.

Key facts

This page summarizes Frank Mottola's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Jul 2026, 17:05.

Change

Previous filing in this sequence was filed on 10 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001804567 Primary reporting owner

Mottola Frank

Relationship: SVP, Chief Tech. Ops. Officer
Address: C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 31 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Performance Share Unit

Award

Transaction value
Shares: +1,650
Change %
Price: $0.000000^*
Shares after: 1,650
Date: 29 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,650
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.